52PA novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors. (5th March 2018) - Medina, J; Hinterberger, M; Testori, M; Geiger, M; Giessel, R; Chaplin, P; Hochrein, H; Lauterbach, H